SEMPLICINI, CLAUDIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.572
EU - Europa 333
AS - Asia 158
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.064
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.570
CN - Cina 130
IT - Italia 95
SE - Svezia 85
GB - Regno Unito 50
FI - Finlandia 48
DE - Germania 20
VN - Vietnam 10
IE - Irlanda 9
HK - Hong Kong 8
IN - India 6
UA - Ucraina 6
BE - Belgio 4
ES - Italia 3
CA - Canada 2
CH - Svizzera 2
FR - Francia 2
NL - Olanda 2
RU - Federazione Russa 2
SA - Arabia Saudita 2
BG - Bulgaria 1
CZ - Repubblica Ceca 1
EU - Europa 1
IR - Iran 1
LU - Lussemburgo 1
NO - Norvegia 1
SG - Singapore 1
SI - Slovenia 1
Totale 4.064
Salva come PNG Salva come JPEG
Città #
Fairfield 614
Woodbridge 488
Ann Arbor 337
Houston 322
Ashburn 289
Chandler 256
Seattle 247
Cambridge 194
Wilmington 186
Princeton 53
San Diego 52
Medford 49
Roxbury 42
Padova 41
Des Moines 40
Beijing 33
Boardman 33
Jacksonville 24
Nanjing 23
Helsinki 17
New York 12
Dong Ket 10
Guangzhou 10
Dublin 9
Hebei 9
Hong Kong 8
Cagliari 6
Florence 6
Los Angeles 6
Norwalk 5
Shanghai 5
Shenyang 5
Cadillac 4
Changsha 4
Dearborn 4
Jiaxing 4
Jinan 4
London 4
Nanchang 4
Zhengzhou 4
Borås 3
Detroit 3
Fuzhou 3
Milan 3
Ogden 3
Phoenix 3
Redwood City 3
Tianjin 3
Wuhan 3
Barcelona 2
Bathinda 2
Boston 2
Brendola 2
Ham-sur-Heure-Nalinnes 2
Hefei 2
Kharkiv 2
Kunming 2
Marano Vicentino 2
Ningbo 2
Pomezia 2
Riyadh 2
San Cesario sul Panaro 2
Venice 2
Vigonza 2
Waanrode 2
Washington 2
Acton 1
Ardabil 1
Baar 1
Buccinasco 1
Butzbach 1
Böblingen 1
Chicago 1
Costa Mesa 1
Council Bluffs 1
Hangzhou 1
Hounslow 1
Indiana 1
Islington 1
Kilburn 1
Las Vegas 1
Lipomo 1
Lonigo 1
Luxembourg 1
Maserà di Padova 1
Mountain View 1
Mumbai 1
New Delhi 1
Orange 1
Pignone 1
Prescot 1
Redmond 1
Selvazzano Dentro 1
Singapore 1
Siracusa 1
Sofia 1
Southend 1
Southwark 1
Taizhou 1
Tappahannock 1
Totale 3.558
Salva come PNG Salva come JPEG
Nome #
Non-neural phenotype of spinal and bulbar muscular atrophy: Results from a large cohort of Italian patients 177
SPP1 genotype and glucocorticoid treatment modify osteopontin expression in Duchenne muscular dystrophy cells 162
Progress in enzyme replacement therapy in glycogen storage disease type II 136
Functional changes in Becker muscular dystrophy: Implications for clinical trials in dystrophinopathies 134
Metabolic myopathies: the challenge of new treatments 120
Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency 117
Genetic modifiers of Duchenne muscular dystrophy and dilated cardiomyopathy 115
1st International Workshop on Clinical trial readiness for sarcoglycanopathies 15-16 November 2016, Evry, France 115
New motor outcome function measures in evaluation of Late-Onset Pompe disease before and after enzyme replacement therapy 114
Enzyme Replacement Therapy for Pompe Disease 111
The italian limb girdle muscular dystrophy registry: Relative frequency, clinical features, and differential diagnosis 110
Muscle MRI in patients with dysferlinopathy: Pattern recognition and implications for clinical trials 108
P. 5.7 Limb-girdle muscular dystrophy type 2E: Clinical, genetic and histopathological features of 27 European patients 104
Muscle MRI and functional outcome measures in Becker muscular dystrophy 102
Spinal Cord Herniation: A Missing Piece in the Pathogenesis of Amyotrophic Lateral Sclerosis and Multiple Sclerosis? 101
Study of Muscle Autophagy and Atrophy Markers in Different Phenotypes of Pompe Disease 101
Clinical and molecular study in a long-surviving patient with MLASA syndrome due to novel PUS1 mutations 99
P. 17.18 Contribution of muscle MRI and< sup> 13 C nuclear magnetic resonance spectroscopy in McArdle disease 98
Therapeutic advances in the management of Pompe disease and other metabolic myopathies 97
LOPED study: Looking for an early diagnosis in a late-onset Pompe disease high-risk population 95
Observational clinical study in juvenile-adult Glycogenosis type 2 patients undergoing Enzyme Replacement Therapy up to 4 years. 92
Assessment of patients with idiopathic inflammatory myopathies and isolated creatin-kinase elevation 91
“I have got something positive out of this situation”: psychological benefits of caregiving in relatives of young people with muscular dystrophy 90
Clinical and genetic spectrum in limb-girdle muscular dystrophy type 2E 87
MRI in sarcoglycanopathies: a large international cohort study 87
Burden, professional support, and social network in families of children and young adults with muscular dystrophies 82
The clinical spectrum of CASQ1-related myopathy 81
Enzyme Replacement Therapy in Juvenile and Adult Late-Onset Glycogenosis Type II 76
MP 5.06 Protocol for enzyme replacement therapy in late-onset glycogenosis type II (GSDII) 71
Prevalence of asymptomatic vertebral fractures in late-onset Pompe disease 70
The role of electrodiagnosis with long exercise test in McArdle disease 68
Teenage exercise is associated with earlier symptom onset in dysferlinopathy: a retrospective cohort study 64
233rd ENMC International Workshop:: Clinical Trial Readiness for Calpainopathies, Naarden, The Netherlands, 15–17 September 2017 61
Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative study 59
Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study 59
The Clinical Outcome Study for dysferlinopathy: An international multicenter study 55
High intra-familiar clinical variability in MORC2 mutated CMT2 patients 53
I-4 Long-term follow-up effects on enzyme replacement treatment of adult form of acid maltase deficiency myopathy 52
Investigating myopathic causes of rhabdomyolysis 52
EMG diagnosis of McArdle disease with long exercise test 50
Integrated care of muscular dystrophies in Italy. Part 2. Psychological treatments, social and welfare support, and financial costs 44
Metabolic myopathies: the challenge of new treatments 44
Assessment of disease progression in dysferlinopathy: A 1-year cohort study 44
Myelopathy or not: a bad case 42
Ablation of collagen VI leads to the release of platelets with altered function 42
Clinical Scales for the Evaluation of Neuromuscular Patients 36
Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventions 36
S2.1 Enzyme replacement therapy (ERT)in Glycogen Storage Disease Type II:the first treatment developed 30
Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease 29
Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years 27
Protocol for enzyme replacement therapy in late-onset glycogenosis type II (GSDII) 24
Lack of COL6/collagen VI causes megakaryocyte dysfunction by impairing autophagy and inducing apoptosis 18
Clinical follow-up and efficacy evaluation in ERT 10
Totale 4.142
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.347
article - articoli 12.940
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 178
Totale 26.465
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019328 0 0 0 0 0 0 0 0 0 0 181 147
2019/2020847 116 44 7 76 104 69 100 91 103 61 41 35
2020/2021672 25 38 18 111 29 49 21 58 83 94 93 53
2021/2022710 29 57 109 55 29 49 49 60 35 14 58 166
2022/2023540 89 52 9 70 92 71 1 40 65 2 35 14
2023/2024230 16 41 25 23 17 30 16 30 20 12 0 0
Totale 4.142